Centessa Pharmaceuticals Announces Poster Presentation of First Preclinical Data for LockBody® Program at 2022 ASCO Annual Meeting
Preclinical data showed that single-agent LB101, PD-L1xCD47 LockBody, delivered systemically led to meaningful tumor regressions…